Introduction
An NADPH oxidase (Nox) is one of the major sources for cellular reactive oxygen species (ROS). Nox enzymes are the structural homologues of phagocytic Nox (gp91phox/Nox2) and constitute a Nox family (Nox1-5, and dual oxidases (Duox1 and 2) ; Lambeth, 2004) . Emerging evidence implicates lower levels of ROS generated by Nox enzymes as a mediator in physiological processes such as inflammation, apoptosis, cell growth and vascularity.
Reactive oxygen radicals have long been thought to be important in neoplastic transformation-a selective advantage in tumor growth or resistance to apoptosis. In this context, it is noteworthy that Nox1 (Mitsushita et al., 2004) , Nox4 (Vaquero et al., 2004; Mochizuki et al., 2006) and Nox5 (Fu et al., 2006) have been suggested to be involved in cell transformation. In the case of Nox1, Ras oncogene and EGF upregulated the Nox1 expression through the mitogen-activated extracellular signal-regulated kinase (MEK)-extracellular signal-regulated kinase (ERK)-dependent pathway and elevated ROS production by oncogenic Ras-induced Nox1 was functionally required for Ras transformation of rat kidney cells, as exhibited in anchorage-independent growth and tumorigenesis in athymic mice (Mitsushita et al., 2004) . Furthermore, Nox1 mediated oncogenic Ras-induced alteration in actin cytoskeleton organization and focal adhesion by downregulating Rho through oxidation of low molecular weight-protein tyrosine phosphatase (Shinohara et al., 2007) . Thus, Nox1 could be a critical mediator of cell transformation by Ras, although Nox1 per se does not possess transforming potential. On the contrary, the role of Nox1 in human cancer development is controversial. While Nox1 overexpression has been seen in human colon cancers (Geiszt et al., 2003) , several studies argued that Nox1 may function in differentiated colon epithelial cells other than promoting mitogenesis and not be associated with tumorigenesis of colon epithelium (Geiszt et al., 2003; Szanto et al., 2005) . Further studies will be needed to settle this issue.
Angiogenesis, that is characterized by the formation of new blood vessels, is required for tumors to grow. It is well established that this event is promoted by upregulation of vascular endothelial growth factor (VEGF), VEGF receptors and matrix metalloproteinases in tumor cells. As for VEGF, ROS derived from Nox have been considered to control VEGF production in some cases: insulin-induced VEGF production appears to be mediated by Nox3 in HepG2 cells (Carnesecchi et al., 2006) . However, the detailed mechanism of Nox-dependent regulation of VEGF expression and its contribution to tumor development have not been clarified at molecular level. One recent study by Arbiser et al. (2002) reported that Nox1 is capable of inducing expression of VEGF in prostate cancer-derived cells. While the discovery underscored the importance of Nox1 as a potent trigger of the angiogenic switch, the regulatory role of Nox1 in VEGF induction was not thoroughly explored, particularly about its functional relationships with Ras signaling pathways. Their established Nox1-overexpressing cell lines turned out to contain an activated RasVal12 mutant, thus causing ambiguous results, as mentioned before (Lambeth, 2004) . Solving this issue could accelerate our understanding of how Nox1 is important in angiogenesis that allows dormant tumors to expand actively. In addition, identification of signaling pathways utilized in Nox1-mediated VEGF expression would have implication for providing useful targets in cancer therapy.
Expression of Ras oncogene is sufficient to transform cell lines and is well known to upregulate VEGF expression (Zachary and Gliki, 2001) . In the present study, we demonstrated that Nox1 is functionally needed for RasVal12-induced upregulation of VEGF expression and neovascularization in tumors in athymic mice. Nox1 transcriptionally controlled VEGF expression by modulating Ras-ERK-dependent phosphorylation of Sp1. Similar requirement of Nox1 for VEGF production was detected in human colon tumor-derived cells. In addition, our study, unlike the model described by others (Arbiser et al., 2002) , revealed a new mechanism in which Nox1 is an essential component of the regulatory machinery for VEGF expression, but the Nox1 activity alone is not sufficient for VEGF induction.
Results

Nox1 mediates oncogenic Ras-induced VEGF production
To investigate the regulatory role of Nox1 in Rasinduced VEGF expression, we first compared normal rat kidney fibroblast (NRK) and K-RasVal12-transformed NRK (KNRK) cells for VEGF expression. Since our previous study (Mitsushita et al., 2004) demonstrated that Nox1 expression is upregulated by K-RasVal12 and Ras oncogene is well known to promote VEGF expression (Zachary and Gliki, 2001) , this biological system could be suitable to analyse the functional role of Nox1 in Ras-signaling leading to VEGF production. The levels of VEGF expression were significantly increased in KNRK cells as compared to NRK cells, as determined by enzyme linked immunosorbent assay (ELISA) and northern blot assay (Figures 1a and b) , which is consistent with others' reports that dominant active RasV12 led to the angiogenic phenotype by inducing VEGF production (Kranenburg et al., 2004) . Treatment of cells with an antioxidant, N-acetyl cysteine (NAC) or a flavoprotein inhibitor, diphenylene iodonium (DPI) decreased expression of VEGF ( Figures  2a and b) . These inhibitors had no appreciable inhibitory effect on cell proliferation during the time period for treatment, as determined by immunostaining of Ki-67: the frequency of Ki-67 positive cells is 74.4 ± 9.7% (n ¼ 3) in mock treated KNRK cells, 68 ± 2.6% (n ¼ 3, P ¼ 0.14 versus mock) in DPI-treated KNRK cells and 82.9±3.9% (n ¼ 3, P ¼ 0.40 versus mock) in NAC-treated KNRK cells. Consistent with this, VEGF production was suppressed in two KNRKderived cell lines, N-7 and M-19 carrying Nox1-specific small-interference RNA (siRNAs) designed for different Nox1 cDNA regions (Mitsushita et al., 2004) as compared to scrambled siRNA-carrying KNRK cells (Neg-1) (Figure 3a) . Notably, the levels of VEGF production decreased, correlating with those of Nox1mRNA expression ( Figure 3b ). As the data excluded a possibility of off-target effect of siRNAs used, we therefore focused on N-7 and Neg-1 cells in the subsequent experiments. Northern blotting also confirmed that ablation of Nox1 by Nox1 RNA interference (RNAi) caused a decrease in VEGF mRNA levels in these cells (Figure 3c ). From these results, we conclude that activated Ras-dependent induction of VEGF Figure 1 Vascular endothelial growth factor (VEGF) expression is increased upon Ras transformation. Normal rat kidney fibroblast (NRK) and K-RasVal12-transformed NRK (KNRK) cells were cultured for 24 h and the culture supernatants were subjected to assay for VEGF protein production (a). The data indicate means ± s.d. of three independent experiments; P* ¼ 0.009. Alternatively, VEGF mRNA levels in both cell lines were analysed by northern blot analysis (b). Densitometric intensity of autoradiographed bands is shown in Supplementary Information, Figure S1 . 28S and 18S rRNAs were used as loading controls. Figure 2 Suppressive effects of diphenylene iodonium (DPI) and N-acetyl cysteine (NAC) on VEGF expression in K-RasVal12-transformed normal rat kidney (KNRK) cells. KNRK cells were treated with DPI (10 mM) or NAC (10mM) for 12 h. VEGF protein production was determined by enzyme linked immunosorbent assay (ELISA) (a). The data represent means ± s.d. of three independent experiments. P* ¼ 0.002 and P** ¼ 0.004 versus none. Alternatively, levels of VEGF mRNAs were analysed by northern blot analysis (b). Densitometric intensity of autoradiographed bands is shown in Supplementary Information, Figure S2 . Figure S3 ). In contrast, transfection of neither Cu/Zn-superoxide dismutase nor Mn-superoxide dismutase changed the level of VEGF, suggesting that depletion of superoxide by these SOD enzymes does not reduce VEGF production (data not shown). As the superoxide generation is increased due to upregulation of Nox1 in KNRK cells (Mitsushita et al., 2004) and this superoxide is rapidly dismutated to H 2 O 2 , the data support the notion that ROS generated by Nox1 mediate the RasVal12-induced expression of VEGF.
To know whether upregulation of the Nox1 activity alone can turn on VEGF production, NRK cells were cotransfected with Nox1, NOXO1 and NOXA1 and processed for VEGF production assay. As shown in Figure 4a , the constitutively active Ras induced VEGF expression in NRK cells 48 h after transfection, which is in agreement with the observation that VEGF is highly expressed in KNRK cells (Figure 1 ). On the contrary, overexpression of Nox1 together with its adaptor proteins did not enhance VEGF production as compared to control vector-transfected cells (Figure 4a ). It should be noted that transfection of Nox1 with adaptor proteins increased superoxide production to the level comparable to that of RasVal12-transfected cells (Figure 4b ). The data indicate that the Nox1 activity alone may not be sufficient for induction of VEGF synthesis, and that Nox1 exerts its regulatory role in concert with an additional signaling pathway(s) triggered by activated Ras. Similar insufficiency of the Nox1 activity alone was seen with VEGF production in human colon cancer CaCO-2 cells, while transfection of RasVal12 increased its production (data not shown).
Sp1 mediates oncogenic Ras-induced VEGF expression via Nox1
Our results indicate that activated Ras-induced upregulation of VEGF expression is controlled at the transcriptional level. Since Sp1 (Milanini et al., 1998) , hypoxia-inducible transcription factor (HIF)-1a (Forsythe et al., 1996) and nuclear factor (NF)-kB (Shukla et al., 2004) have been reported to transactivate VEGF promoter, we investigated whether these transcription factors are responsible for upregulation of VEGF by the Ras-Nox1 signaling. Treatment of KNRK cells with an Sp1 inhibitor, mithramycin blocked VEGF production in a dose-dependent manner ( Figure 5a ). This prompted us to test whether the Nox1 activity affects Sp1 binding to a VEGF-A promoter by electrophoresis mobility shift assay (EMSA). Nuclear extracts were prepared from KNRK cells treated with various inhibitors and incubated with a 32 P-labeled oligonucleotide probe encompassing a Sp1 binding site (nt-59 to-36) in the VEGF-A promoter. Formation of the protein-DNA complexes was observed with untreated control cells: Sp1 comprises the upper portion of the slower-migrating complexes as reported earlier (Chupreta et al., 2000; Figure 5 ). Sp1 complex formation was significantly attenuated by DPI or NAC treatment and Sp1 binding was confirmed by super-shift assay with anti-Sp1 antibodies ( Figure 5b ). Then, nuclear extracts were prepared from M-19, N-7 and Neg-1 cells and tested for the ability to induce Sp1-DNA complex formation. When compared with scrambled siRNA, targeting of Nox1 with Nox1siRNAs significantly impaired formation of a complex on the Sp1 probe (Figure 5c ), In control experiments, EMSA showed that no binding of the nuclear proteins to consensus HIF-1a (nt-907 to-884) and NF-kB (nt-278 to-255) sites in the VEGF-A-promoter region was detected (data not shown), suggesting that HIF-1a and NF-kB are not involved in Ras-induced upregulation of VEGF expression. Taken together, the results demonstrate that Nox1 is required for a Ras-induced increase in Sp1 binding to the VEGF-A promoter. Additionally, the complex formation was suppressed by treatment of KNRK cells with an MEK inhibitor, PD98059 (Figure 5d ), indicating that Sp1 binding to the VEGF-A promoter is enhanced in an ERK phosphorylation-dependent manner.
Nox1 mediates Ras/ERK-induced phosphorylation of Sp1
There has been some evidence that ERK activates the Sp1 activity by causing Sp1 phosphorylation (Milanini et al., 1998; Chupreta et al., 2000) . Our data, as given above, also showed that an MEK inhibitor, PD98059 prevents K-RasV12-induced activation of Sp1 binding to the VEGF-A promoter in KNRK cells. We therefore sought to determine whether Nox1 is involved in the Ras/ERK signaling-dependent modulation of Sp1 phosphorylation. Cells were metabolically labeled with 32 P-orthophosphate in the presence or absence of various inhibitors and cell lysates were subjected to immunoprecipitation with anti-Sp1 antibodies. Importantly, DPI treatment of KNRK cells reduced phosphorylation of Sp1 (Figure 6a ). Consistent with this, the level of Sp1 phosphorylation was lower in N-7 cells than that in Neg-1 cells (Figure 6b ). NAC also showed an inhibitory effect on phosphorylation of Sp1 (data not shown). The data suggest that Nox1-generated ROS is important in upregulation of Sp1 phosphorylation in KNRK cells. We next determined whether Nox1 affects the ERK activity. Our previous studies revealed that the ERK activation is constitutively sustained in KNRK cells, while it is transient in response to agoniststimulation in NRK cells (Mitsushita et al., 2004) . This ERK activation was responsible for stimulation of Sp1 phosphorylation in KNRK cells, because PD98059 blocked phosphorylation of Sp1 (Figure 6a ), which correlated well with suppression of VEGF production by the MEK inhibitor (Figure 7a ). Moreover, immunoblotting with anti-phospho-ERK peptide antibodies shows that the level of ERK phosphorylation was attenuated moderately in M-19 cells and more severely in N-7 cells, when compared to Neg-1 cells (Figure 7b ). This Nox1 dose dependency in ERK activation supports the notion that Nox1 is required for Ras-dependent ERK activation that leads to Sp1 phosphorylation.
Nox1 regulates VEGF production in KNRK-derived tumors To explore VEGF production in tumors, tumor tissues were isolated from Neg-1 and N-7 cell-injected mice and ELISA was carried out for VEGF in cell lysates. We . Cell lysates were prepared and Sp1 proteins were immunoprecipitated with rabbit anti-Sp1 antibodies and analysed by SDS-polyacrylamide gel electrophoresis (PAGE), followed by autoradiography.
Nox1 mediates oncogenic Ras-induced VEGF upregulation D Komatsu et al previously observed that N-7 cells exhibit the remarkably reduced rate of tumor growth as compared to Neg-1 cells (Mitsushita et al., 2004) . High-level expression of VEGF was detectable in Neg-1 tumors with augmented vascularity characteristic of newly growing blood vessels (Figures 8a and b) . In contrast, little or no capillary tube was formed in N-7 tumors that are accompanied by robustic necrosis (Figure 8b ). The data indicate that Nox1 is a critical regulator of VEGF expression in tumors in vivo, contributing to tumor angiogenesis.
VEGF is one of the critical regulators of tumor angiogenesis that lead to progression to a growing tumor. Consistent with this view, a marked increase in the VEGF level was detected in colon adenocarcinoma samples isolated from patients, while it remained at the basal level in neighboring normal intestine tissues (Figure 9a ). When a colorectal cancer cell line, CaCO-2 were treated with DPI or transiently transfected with Nox1siRNAs, VEGF expression was significantly suppressed (Figure 9b) . Similar results were obtained with another colon cancer cell line, T84 (data not shown). As Nox1 is known to be biologically active in these cell lines (our unpublished data; Geiszt et al., 2003) , the data implicate the requirement of Nox1 for VEGF expression in colon cancer cells, as in the case of dominant active Ras-induced upregulation of VEGF in KNRK cells.
Discussion
Vascular endothelial growth factor is a key regulator of tumor vascularization. Expression of Ras oncogene is well known to upregulate VEGF expression, but the signaling mechanism underlying the regulation is not fully understood. In this study, we found that Nox1 exerts a critical mediating role in oncogenic Ras-induced upregulation of VEGF expression. Nox1 controlled VEGF production at the transcriptional level by mediating Ras-ERK-dependent phosphorylation of Sp1. An excellent correlation among Nox1 expression, the ERK activity, the Sp1 binding activity, and the amount of VEGF produced was detected by employing Nox1 RNAi. Requirement of Nox1 for Ras-induced angiogenic processes was demonstrated by a marked decrease in both VEGF production and vascularity in tumors derived from Nox1-silenced KNRK cells. Furthermore, an increased expression of VEGF was detected in human colon cancer tissues and this signaling process needed the Nox1 activity, as in the case of RasVal12-transformed rat kidney cells. Our Nox1 mediates oncogenic Ras-induced VEGF upregulation D Komatsu et al findings provide the first clear indication that Ras transformation contributes to angiogenesis and angiogenic signal transduction by upregulating VEGF generation through Nox1-derived ROS. The findings agree with those in our previous study, which revealed that increased generation of ROS by oncogenic Ras-induced Nox1 is an important rate-limiting step for Ras transformation phenotypes (Mitsushita et al., 2004) . Earlier studies by Arbiser et al. (2002) described that overexpression of Nox1 alone can upregulate synthesis of VEGF mRNAs in NIH3T3 cells and prostate cancer cells, which led them to postulate that Nox1 is a potent trigger of the angiogenic switch, permitting tumor vascularization and growth. Their observations, however, were not conclusive in that Nox1 was accidentally introduced into RasVal12-transformed NIH3T3 cells instead of NIH3T3 cells and there is a strong possibility that the assay of VEGF production using this stable line misread the effect of activated Ras as that of Nox1 itself, as stated later (Lambeth, 2004) . Nor was the signaling mechanism including the transcriptional regulation of VEGF expression investigated. We re-evaluated the role of Nox1 in VEGF expression with a special focus on its relationships with Ras signaling pathways. Notably, our data indicate that overexpression of Nox1 with its adaptor proteins failed to increase VEGF expression in NRK cells, while ectopic expression of RasVal12 was sufficient to trigger VEGF production. We therefore speculate that the Nox1 activation is certainly a necessary step for RasVal12-induced upregulation of VEGF, but the Nox1 activity alone is insufficient to induce VEGF expression. Perhaps, Nox1 acts in concert with another effector pathway, Ras-Raf-MEK-ERK kinase cascade, to fully activate VEGF expression through the Sp1 transcription factor. Still, VEGF expression was upregulated upon overexpression of Nox1 in a prostate cancer cell line DU-145 (Arbiser et al., 2002) . This observation appears to be against our hypothesis given above, proposed for the regulatory role of Nox1. However, as the activity of the ERK kinase is constitutively activated in progressive prostate cancer cells (Gioeli et al., 1999) , it is possible that spontaneously activated ERK cooperated with exogenously overexpressed Nox1, resulting in acceleration of VEGF expression in DU-145 cells. Sustaining of ERK activation by Nox1 might be a critical event, as discussed below. Of course, we do not formally exclude the possibility that Nox1 coordinately acted with a signaling pathway(s) other than the ERK kinase in DU-145 cells.
Our study demonstrated that Nox1 mediates ERKdependent phosphorylation of Sp1 that is responsible for Ras-induced upregulation of VEGF expression. The involvement of ERK in regulation of Sp1 activity, such as Sp1-binding to the promoters of target genes and Sp1 transactivation activity, has been reported in various biological systems (Milanini et al., 1998; Merchant et al., 1999; Chupreta et al., 2000) . However, it is still undetermined whether ERK directly phosphorylates Sp1. Evidence implicated the existence of the putative Sp1 kinase capable of phosphorylating Sp1 in response to ERK activation rather than direct phosphorylation of Sp1 by ERK (Chupreta et al., 2000) . Nonetheless, our results, together with that of others', indicated that at least ERK activation is an essential step for induction of Sp1 phosphorylation, because an MEK inhibitor Figure 9 Vascular endothelial growth factor (VEGF) production in colon cancers and colon cancer-derived cell lines. (a) Colon adenocarcinoma and neighboring normal tissues were isolated from patients, cell lysates were prepared and VEGF levels were determined. The data represent means ± s.d. of three different samples. P ¼ 0.04. (b) CaCO-2 cells were treated or untreated with 5 mM diphenylene iodonium (DPI) for 12 h and levels of VEGF in the culture media were determined. Data (% control (untreated)) represent means of duplicated experiments. P* ¼ 0.009 versus DPI(À). Similar results were obtained with separate experiments. (c) Alternatively, CaCO-2 cells were plated into a 24-well plate, transfected with scrambled siRNA (1 mg) or Nox1siRNAs (RNAi-3) (1 mg), and subjected to VEGF production assay. The data represent means ± s.d. of three independent experiments. P* ¼ 0.02 versus scrambled. To verify suppression of Nox1 expression by Nox1 RNAi, crude membranes of transfected cells were isolated by spinning the homogenates following sonication of cells in hypotonic buffer and extracted in RIPA buffer. Membrane extracts were immunoprecipitated with rabbit anti-Nox1 antibodies and then immunoblotted with the same antibodies.
Nox1 mediates oncogenic Ras-induced VEGF upregulation D Komatsu et al blocked it. In this regard, it is noteworthy that ablation of the ERK activity by Nox1-specific siRNAs led to transcriptional suppression of VEGF in Nox1-knockeddown KNRK cells (Figures 5c, 5d and 7b) . Then, the question is how Nox1 regulates the ERK activity. In general, tyrosine phosphorylation is known to modulate the enzymatic activity and tyrosine phosphorylation levels are controlled through the balance between phosphorylation by tyrosine kinases and dephosphorylation by protein tyrosine phosphatases (PTPs). Recently, H 2 O 2 -induced oxidation of redox-sensitive cysteine residues at the catalytic pocket of PTPs has been shown to deactivate their activities (Chiarugi et al., 2001; Rhee et al., 2003) . For instance, EGF receptor tyrosine kinase-mediated signal transduction was sustained by oxidation of PTP1B with intracellular ROS (Lee et al., 1998) . PDGF triggered H 2 O 2 -induced oxidation and inhibition of SHP-2, the SH 2 -containing PTP, which facilitated mitogenic signaling in response to the growth factor (Meng et al., 2002) . In the case of ERKs, MAP kinase phosphatase (MKP)-1, -2 and -3 antagonize ERK 1/2 by catalysing dephosphorylation of their tyrosine-phosphorylated, activated forms (Kondoh and Nishida, 2007) and ERKs are activated in response to generation of H 2 O 2 (Fialkow et al., 1994) . Thus, one interesting possibility is that Nox1 maintains the oncogenic Ras/MEK-induced activated state of ERK by deactivating MKPs through oxidation of redoxsensitive cysteines and thereby contributes to Ras/ERK/ Sp1-dependent upregulation of VEGF (Figure 10 ). In fact, putative redox-sensitive cystein residues are conserved in MKPs (Kamata et al., 2005) . The study is currently underway to test this possibility.
Accumulating evidences show possible regulatory roles of Nox-derived ROS in VEGF production. Insulin stimulation was suggested to induce Nox3-derived H 2 O 2 in HepG 2 cells and thereby cause VEGF production through the ERK signaling-dependent activation of Sp1 (Carnesecchi et al., 2006) . Shock wave-induced VEGF expression in osteoblasts was mediated by Ras-induced superoxide and ERK-dependent HIF-1a activation, although the nature of Nox involved was not identified (Wang et al., 2004) . Additionally, H 2 O 2 generated by a Nox-like enzyme increased VEGF expression in human keratinocytes and wound healing, which required activation of Sp1 (Sen et al., 2002) . Our present finding that Nox1 acts as one of effectors in regulation of VEGF expression during tumor vascularity provides a further support for biological importance of Nox enzymes in VEGF gene activation.
In summary, the present studies provide evidence that Nox1, at least in part, regulates the Ras-ERK signaling pathway leading to Sp1-dependent transcription of VEGF in Ras-transformed cells and its associated angiogenesis. Given the well-established role of Ras oncogene in the pathogenesis of human cancers, most, if not all, of the above scenario may apply to angiogenic processes associated with malignant human tumors. Indeed, Nox1 requirement for VEGF production was demonstrated in colorectal cancer-derived cells (Figure 9 ). Thus, our study provides a significant insight into the molecular mechanism of tumor angiogenesis and the biopharmacological modulation of Nox1 may benefit prevention of tumor expansion.
Materials and methods
Cell culture and materials
Normal rat kidney fibroblast cells and KNRK cells were obtained from American Type Culture Collection (Manassas, VA, USA). KNRK cell lines stably expressing scrambled siRNA (Neg-1) and Nox1siRNAs (N-7 and M-19) have been isolated, characterized and referred to as Neg-1, siNox1-N-7 and siNox1-M-19 cell lines, respectively, in our previous studies (Mitsushita et al., 2004) . Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented Figure 10 A model for oncogenic Ras-induced upregulation of vascular endothelial growth factor (VEGF) through Nox1. Oncogenic Ras (RasVal12) activates the Nox1 expression through the Raf-MEK-ERK pathway and increases ROS production. An increase in Nox1-generated ROS may aid the maintenance of maximal tyrosine phosphorylation of ERK possibly by inactivating of a MAPK phosphatase and thereby contribute to upregulation of VEGF synthesis that is mediated by the Ras-ERK-Sp1-dependent pathway.
Nox1 mediates oncogenic Ras-induced VEGF upregulation D Komatsu et al with 10% fetal bovine serum (FBS). To maintain the stably transfected cell lines, hygromycin (100 mg/ml) was added to the culture medium. Monoclonal anti-HA antibodies (H-7), rabbit anti-ERK antibodies, rabbit anticatalase antibodies and NAC were purchased from Sigma (Milwaukee, WI, USA) and proteinA-Sepharose and poly-dI-dC from GE-Healthcare (Buckinghamshire, UK). DPI and PD98059 were obtained from CalBiochem (Lajolla, CA, USA), rabbit anti-PECAM1 antibodies from Santa Cruz (Santa Cruz, CA, USA), rabbit anti-Sp1 antibodies from UBI (Lakeolasid, NY, USA) and rabbit anti-phospho-ERK (Thr202/Tyr204) antibody from Cell Signaling (Danvers, MA, USA). Polyclonal rabbit antibodies to human Nox1 was raised against its COOHterminal 21 amino-acid residues following crosslinking to KLH and affinity purified. Human catalase expression plasmids (PS3 CAT) and pcDNA3.0-RasVal12 were provided by Dr T Finkel and Dr J Downward, respectively.
Transfection and construction of siRNAs Transfection was carried out by using Lipofectamine 2000 (Invitrogen, Carsload, CA, USA) according to the manufacturer's protocol. Nox1siRNA (RNAi-3) was designed based on human Nox1cDNA sequences: 5 0 -GCGTGGCTTCAGCAT GGAA-3 0 and subcloned into pSilencer vector (Ambion, Austin, TX, USA).
VEGF production assay
The VEGF-A levels of culture supernatant were determined by using ELISA kits (Duoset; R&D system, Minneapolis, MN, USA) according to manufacturer's instructions. Culture supernatant (100 ml) or tumor extract (500 mg) was applied to 96-well plates.
Northern blot analysis and RT-PCR Total RNAs were extracted from cells at the subconfluent stage by using Trizol (Invitrogen). Northern blot analysis was performed with the standard method (Sambrook and Russell, 2001) . Total RNAs (10 mg) were separated by agarose gel electrophoresis and RNA blots were probed with a full length of rat VEGF-A cDNA labeled with 32 P by using random primers labeling system (Invitrogen) and [a- 32 P]dCTP (111 TBq/mmol, Muromachi Pharm. Co., Tokyo, Japan). For reverse transcription (RT)-PCR, total RNAs were prepared as described above and cDNA synthesis and PCR were performed as described previously (Mochizuki et al., 2006) .
Preparation of nuclear extracts
Cells were lysed in lysis buffer (10 mM Tris-HCl pH 7.9, 10 mM KCl, 2 mM MaCl 2 , 0.1 mM EDTA and 0.7% NP-40) for 10 min at 4 1C, lysates were centrifuged at 500 g for 5 min. The resulting pellets were further lysed with buffer (40 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.9, 350 mM NaCl, 2 mM MgCl 2 , 1mM EDTA, 20% glycerol, 1% NP-40, and 1 mM phenylmethylsulfonyl fluoride (PMSF)) for 20 min at 4 1C, lysates were spun at 12 000 g for 10 min and the supernatants were used as nuclear extracts. Protein concentrations of extracts were determined using a Bio-Rad protein assay kit (Bio-Rad, Hercules, CA, USA).
Electrophoretic mobility shift assay A rat VEGF-A promoter oligonucleotide probe (5 0 -GGC CTTTGGGGGCGGGGCCAGATT-3 0 ), that codes for a Sp1 consensus binding site, (nt-59 to-36) was labeled with 32 P by using random primers labeling system (Invitrogen) and [a-
32 P]dCTP (111 TBq/mmol, Muromachi Pharm. Co.). Nuclear extracts (2 mg), prepared as described above, were incubated for 30 min at room temperature with a binding buffer containing 20 mM HEPES pH 7.9, 50 mM KCl, 5% glycerol, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, 1 mg/ml poly-dI-dC and 10 5 cpm of 32 P-labeled probes with or without 100-fold excess of Sp1 cold probes. To identify specific binding of Sp1 to DNA, anti-Sp1 antibodies (1 mg) were added to the binding reaction mixtures for 30 min at 4 1C. Samples were electrophoresed through 4% polyacrylamide gel and radioactive bands were detected by autoradiography.
Phosphorylation analysis KNRK cells were metabolically labeled with 32 P in phosphatefree DMEM (Invitrogen) supplemented with 10% dialysed FBS and 0.1 mCi/ml of phosphorus-32 P (MP Biomedicals, Irvine, CA, USA) for 4 h. Cells were harvested and subjected to nuclear extraction as described above. The nuclear extracts were then immunoprecipitated with anti-Sp1 antibodies and proteins bound to proteinA-Sepharose resins were analysed by SDS-polyacrylamide gel electrophoresis (PAGE), followed by autoradiography. Total Sp1 was detected by immunoblotting with anti-Sp1 antibodies after immunoprecipitation with anti-Sp1 antibodies. For ERK phosphorylation assay, cells were treated or untreated with PD98059 for the indicated time intervals and lysed in Laemmli sample buffer. Samples were analysed by SDS-PAGE, followed by immunoblotting with anti-phospho ERK antibodies (Cell Signaling).
Measurement of reactive oxygen species
Reactive oxygen was measured by using luminal luminescence according to the published method (Cheng et al., 2004) . Cells (5 Â 10 5 ) were trypsinized and suspended in Hanks' buffer supplemented with calcium/magnesium (HBCM). Cell suspension was mixed with 200 mM luminol and 0.8 unit horseradish peroxidase in 500 ml HBCM and incubated at room temperature for 20 min. Luminescence was then quantified by a Luminescencer-PSN (ATTO, Tokyo, Japan).
Immunoblotting and immunoprecipitation
Cells were lysed in lysis buffer (20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF and 1% TritonX-100) or RIPA buffer (50 mM Tris-HCl pH 7.2, 1% NP-40, 0.1% sodium deoxycholate, 150 mM NaCl, 4 mM EDTA, and 1 mM PMSF) for 20 min, lysates were spun at 12 000 g for 10 min, and the supernatants were subjected to immunoblotting or immunoprecipitation as described (Shinohara et al., 2007) .
Immunohistochemistry
Tissue sections on slides were deparaffinized, dehydrated and made free in endogenous peroxidase activity as described previously (Omachi et al., 2007) . Antigen retrieval was carried out by incubating tissue sections in a microwave in 10 mM TrisHCl (pH 8.0) buffer containing 1 mM EDTA. Sections were incubated with anti-PECAM1 antibodies and subsequently with HRP-conjugated secondary antibodies. 3,3 0 -diaminobenzidine was used as a chromagen. After counterstaining with hematoxylin, samples were observed under a microscope.
Tumorigenecity analysis
Trypsinized cells (1 Â 10 6 ) were resuspended in 0.2 ml of phosphate-buffered saline (PBS) and injected s.c. into athymic mice as described (Mitsushita et al., 2004) . Tumors formed were isolated after 4 weeks. A half of these was used for immunohistochemistry and the other half was homogenized in Nox1 mediates oncogenic Ras-induced VEGF upregulation D Komatsu et al PBS containing 0.5% TritonX-100 and 1 mM PMSF and subjected to VEGF production assay and immunoblotting.
Patient samples
The analysis of human tissues was approved by the Human Research Ethical Committee of Shinshu University. Colon cancer tissues were surgically removed from patients and processed for analysis.
Statistical analysis
The statistical analysis was performed with Student's t-test. For multiple treatment groups, a factorial ANOVA followed by Bonferroni's t-test was applied. Differences with values Po0.05 were considered to be statistically significant.
